MedTrace Logo

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

NCT01178827 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-02-26

Study results available
· View outcomes & findings →

Summary

This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory impairment.

Conditions

Interventions

DRUG

trospium chloride

trospium chloride (60mg) once daily for 10 days

DRUG

oxybutynin IR

oxybutynin IR (5 mg) three times daily for 2 days

DRUG

oxybutynin IR placebo

oxybutynin IR placebo three times daily for 2 days

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01178827 on ClinicalTrials.gov